Organon & Co
NYSE:OGN
Organon & Co
Cash from Financing Activities
Organon & Co
Cash from Financing Activities Peer Comparison
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Organon & Co
NYSE:OGN
|
Cash from Financing Activities
-$569m
|
CAGR 3-Years
36%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Financing Activities
-$15.8B
|
CAGR 3-Years
-32%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-7%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Financing Activities
$8.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Financing Activities
$26.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Financing Activities
-$4.8B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
17%
|
CAGR 10-Years
-5%
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Financing Activities
$3.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Organon & Co's Cash from Financing Activities?
Cash from Financing Activities
-569m
USD
Based on the financial report for Dec 31, 2023, Organon & Co's Cash from Financing Activities amounts to -569m USD.
What is Organon & Co's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
33%
Over the last year, the Cash from Financing Activities growth was -31%. The average annual Cash from Financing Activities growth rates for Organon & Co have been 36% over the past three years , 33% over the past five years .